Compare MOBX & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOBX | ABVC |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 46 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 50.5M |
| IPO Year | N/A | 2009 |
| Metric | MOBX | ABVC |
|---|---|---|
| Price | $0.81 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.7M | 48.5K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.61 |
| 52 Week High | $1.44 | $4.02 |
| Indicator | MOBX | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 41.61 |
| Support Level | $0.78 | $1.15 |
| Resistance Level | $0.92 | $1.52 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 61.39 | 55.62 |
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.